PE20210165A1 - Un derivado de oxopiridina sustituido - Google Patents

Un derivado de oxopiridina sustituido

Info

Publication number
PE20210165A1
PE20210165A1 PE2020001563A PE2020001563A PE20210165A1 PE 20210165 A1 PE20210165 A1 PE 20210165A1 PE 2020001563 A PE2020001563 A PE 2020001563A PE 2020001563 A PE2020001563 A PE 2020001563A PE 20210165 A1 PE20210165 A1 PE 20210165A1
Authority
PE
Peru
Prior art keywords
amino
oxopyridine
methylhexanoyl
cyanophenyl
pyridine
Prior art date
Application number
PE2020001563A
Other languages
English (en)
Inventor
Mario Lobell
Hartmut Schirok
Adrian Tersteegen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20210165A1 publication Critical patent/PE20210165A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE AL COMPUESTO 5-({6-AMINO-2-[4-(5-CLORO-2-CIANOFENILO)-5-METOXI-2-OXOPIRIDINA-1(2H)-IL]-3-METILHEXANOIL}AMINO)PIRAZOL[1,5-A]PIRIDINA-3-CARBOXAMIDA, ASI COMO LOS COMPUESTOS 5-({6-AMINO-2-[4-(5-CLORO-2-CIANOFENILO)-5-METOXI-2-OXOPIRIDINA-1(2H)-IL]-3-METILHEXANOIL}AMINO)PIRAZOL[1,5-A]PIRIDINA-3-CARBOXAMIDA TRIFLUOROACETATO Y 5-({(2S)-6-AMINO-2-[4-(5-CLORO-2-CIANOFENILO)-5-METOXI-2-OXOPIRIDINA-1(2H)-IL]-3-METILHEXANOIL}AMINO)PIRAZOL[1,5-A]PIRIDINA-3-CARBOXAMIDA. DICHO COMPUESTO ES INHIBIDOR DE CALICREINA PLASMATICA (PK) SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS TROMBOTICOS O TROMBOEMBOLICOS, EDEMAS, TRASTORNOS OFTALMICOS.
PE2020001563A 2018-04-10 2019-04-03 Un derivado de oxopiridina sustituido PE20210165A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166490 2018-04-10
PCT/EP2019/058398 WO2019197244A1 (en) 2018-04-10 2019-04-03 A substituted oxopyridine derivative

Publications (1)

Publication Number Publication Date
PE20210165A1 true PE20210165A1 (es) 2021-01-26

Family

ID=61965754

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001563A PE20210165A1 (es) 2018-04-10 2019-04-03 Un derivado de oxopiridina sustituido

Country Status (16)

Country Link
US (1) US11884660B2 (es)
EP (1) EP3774796B1 (es)
JP (1) JP7333336B2 (es)
KR (1) KR20200141445A (es)
CN (1) CN111902414B (es)
AU (1) AU2019251699B2 (es)
BR (1) BR112020018237A2 (es)
CA (1) CA3096480A1 (es)
DK (1) DK3774796T3 (es)
ES (1) ES2922533T3 (es)
IL (1) IL277811B2 (es)
MX (1) MX2020010635A (es)
PE (1) PE20210165A1 (es)
SA (1) SA520420308B1 (es)
SG (1) SG11202008352YA (es)
WO (1) WO2019197244A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046164A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
EP3271332A1 (de) 2015-03-19 2018-01-24 Bayer Pharma Aktiengesellschaft Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
ES2922533T3 (es) 2022-09-16
JP7333336B2 (ja) 2023-08-24
KR20200141445A (ko) 2020-12-18
AU2019251699A1 (en) 2020-09-24
SG11202008352YA (en) 2020-09-29
JP2021521132A (ja) 2021-08-26
EP3774796A1 (en) 2021-02-17
US20210147414A1 (en) 2021-05-20
SA520420308B1 (ar) 2022-09-29
MX2020010635A (es) 2020-10-28
AU2019251699B2 (en) 2024-02-29
IL277811B1 (en) 2023-08-01
EP3774796B1 (en) 2022-04-27
CN111902414B (zh) 2023-08-04
US11884660B2 (en) 2024-01-30
WO2019197244A1 (en) 2019-10-17
DK3774796T3 (da) 2022-07-18
BR112020018237A2 (pt) 2020-12-29
IL277811B2 (en) 2023-12-01
IL277811A (en) 2020-11-30
CA3096480A1 (en) 2019-10-17
CN111902414A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
CO2021002651A2 (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX2016010572A (es) Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
PE20210165A1 (es) Un derivado de oxopiridina sustituido
UY38525A (es) 1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas
MA41051B1 (fr) Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CO6270288A2 (es) Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal
BR112021019643A2 (pt) Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
PE20170323A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
MX368496B (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
PH12020552261A1 (en) Proteasome activity enhancing compounds
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
CO2022000422A2 (es) Inhibidores de enzimas
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos